Klotho Neurosciences, Inc. (KLTO)
NASDAQ: KLTO · Real-Time Price · USD
0.471
+0.013 (2.73%)
At close: Mar 9, 2026, 4:00 PM EDT
0.466
-0.006 (-1.19%)
After-hours: Mar 9, 2026, 4:41 PM EDT
Company Description
Klotho Neurosciences, Inc. develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders.
Its lead gene therapy product candidates consist of KLTO-101 for the treatment or prevention of Alzheimer’s disease; and KLTO-202, a gene therapy product for treatment and prevention of Lou Gehrig’s disease.
The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024.
Klotho Neurosciences, Inc. is based in Omaha, Nebraska.
Klotho Neurosciences, Inc.
| Country | United States |
| Founded | 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Joseph Sinkule |
Contact Details
Address: 13576 Walnut Street, Suite A Omaha, Nebraska 68144 United States | |
| Phone | 833 931 6330 |
| Website | klothoneuro.com |
Stock Details
| Ticker Symbol | KLTO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001907223 |
| CUSIP Number | 49876K103 |
| ISIN Number | US49876K1034 |
| Employer ID | 86-2727441 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Joseph Sinkule Pharm.D. | Founder, Chief Executive Officer, Chairman of the Board and Secretary |
| Jeffrey LeBlanc | Chief Financial Officer |
| Dr. Shalom Z. Hirschman M.D. | Medical Advisor and Director |
| Peter J. Moriarty | Chief Business Officer |
| Dr. Miguel Chillon Rodriguez | Chief Scientific Officer and Consultant |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 4, 2026 | 8-K | Current Report |
| Mar 2, 2026 | 8-K | Current Report |
| Feb 24, 2026 | 424B3 | Prospectus |
| Feb 24, 2026 | 8-K | Current Report |
| Feb 17, 2026 | 8-K | Current Report |
| Jan 26, 2026 | DEFR14A | Filing |
| Jan 23, 2026 | DEF 14A | Other definitive proxy statements |
| Jan 12, 2026 | PRE 14A | Other preliminary proxy statements |
| Dec 12, 2025 | EFFECT | Notice of Effectiveness |
| Dec 8, 2025 | 8-K | Current Report |